Gilead Partners With US on HIV Drug for Countries in Need

The US State Department announces an initiative to bring Gilead Sciences’ drug Lenacapavir to market in high-burden HIV countries, according to a press release.

• Gilead is offering this product at cost and without a profit, the agency says

To contact the reporter on this story:
Matthew James Mcarthur in New York at mmcarthur8@bloomberg.net

To contact the editor responsible for this story:
Kasia Klimasinska at kklimasinska@bloomberg.net

© 2025 Bloomberg L.P. All rights reserved. Used with permission.